COMMUNIQUÉS West-GlobeNewswire

-
Arvinas Announces Retirement of Chief Executive Officer and Succession Plan
09/07/2025 -
Purespring Therapeutics announce FDA IND clearance for Phase I/II clinical trial for primary IgA nephropathy (IgAN)
09/07/2025 -
Tilray Brands to Announce Fourth Quarter and Fiscal Year 2025 Financial Results on July 28, 2025
09/07/2025 -
Krystal Biotech Announces First Patient Dosed in Phase 1/2 Trial of KB801 for the Treatment of Neurotrophic Keratitis
09/07/2025 -
Axsome Therapeutics to Report Second Quarter 2025 Financial Results on August 4
09/07/2025 -
Nusano Achieves Key Technology Milestone Enabling Simultaneous Production of Multiple Radioisotopes
09/07/2025 -
Neumora Therapeutics Announces Initiation of Phase 1 Clinical Study of M4 Positive Allosteric Modulator NMRA-861
09/07/2025 -
Aurora Spine Announces Initial Surgeries using its AERO™ Lumbar Fusion System
09/07/2025 -
Glucose Health, Inc. Formulations Have Always Been Free of Artificial Colors & Synthetic Dyes—Our Competitors Are Only Playing Catch-Up
09/07/2025 -
Communiqué de presse : Sanofi fait galoper Zeus, le cheval mécanique de la cérémonie d’ouverture des Jeux Olympiques, au Mont-Saint-Michel
09/07/2025 -
Altimmune Announces Initiation of RESTORE Phase 2 Trial Evaluating the Efficacy and Safety of Pemvidutide in Alcohol-Associated Liver Disease (ALD)
09/07/2025 -
ProKidney to Participate in the H.C. Wainwright 4th Annual Kidney Virtual Conference
09/07/2025 -
Rezolute Announces Presentation of Participant Baseline Data from its Fully Enrolled Phase 3 Study of Ersodetug in Congenital Hyperinsulinism at the Upcoming Annual Meeting of the Endocrine Society (ENDO 2025)
09/07/2025 -
BriaCell Patient Achieves Sustained Complete Resolution of Lung Metastasis in Bria-OTS™ Metastatic Breast Cancer Study
09/07/2025 -
Theratechnologies présente ses résultats financiers pour le deuxième trimestre de 2025
09/07/2025 -
Theratechnologies Reports Financial Results for the Second Quarter 2025
09/07/2025 -
Atsena Therapeutics Announces Alignment with FDA on Regulatory Pathway to Approval for ATSN-201 in X-Linked Retinoschisis (XLRS)
09/07/2025 -
Artelo Biosciences Announces Positive Preclinical Efficacy Data for ART26.12 in Osteoarthritis Pain at the 35th Annual International Cannabinoid Research Society Symposium
09/07/2025 -
KALA BIO Announces Completion of Enrollment in CHASE Clinical Trial Evaluating KPI-012 for the Treatment of Persistent Corneal Epithelial Defect (PCED)
09/07/2025
Pages